Listed

Foghorn Therapeutics Inc.

FHTXNasdaqCIK 1822462HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$16.1m, Q2 FY2026
Operating income−$8.8m, Q2 FY2026
Net income−$7.2m, Q2 FY2026
Foghorn Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m17.5Revenue, Q3 FY2023, three months to 2023-09-30$17.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure5.8Revenue, Q4 FY2023, three months to 2023-12-31$5.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure5.1Revenue, Q1 FY2024, three months to 2024-03-31$5.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure6.9Revenue, Q2 FY2024, three months to 2024-06-30$6.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure7.8Revenue, Q3 FY2024, three months to 2024-09-30$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure2.9Revenue, Q4 FY2024, three months to 2024-12-31$2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure6.0Revenue, Q1 FY2025, three months to 2025-03-31$6.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure7.6Revenue, Q2 FY2025, three months to 2025-06-30$7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure8.2Revenue, Q3 FY2025, three months to 2025-09-30$8.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure9.2Revenue, Q4 FY2025, three months to 2025-12-31$9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure3.3Revenue, Q1 FY2026, three months to 2026-03-31$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure16.1Revenue, Q2 FY2026, three months to 2026-06-30$16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Research and development$m26.3Research and development, Q3 FY2023, three months to 2023-09-30$26.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure24.2Research and development, Q4 FY2023, three months to 2023-12-31$24.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure25.5Research and development, Q1 FY2024, three months to 2024-03-31$25.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure23.8Research and development, Q2 FY2024, three months to 2024-06-30$23.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure24.7Research and development, Q3 FY2024, three months to 2024-09-30$24.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure20.5Research and development, Q4 FY2024, three months to 2024-12-31$20.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure21.6Research and development, Q1 FY2025, three months to 2025-03-31$21.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure21.8Research and development, Q2 FY2025, three months to 2025-06-30$21.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure20.0Research and development, Q3 FY2025, three months to 2025-09-30$20.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure22.0Research and development, Q4 FY2025, three months to 2025-12-31$22.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure18.3Research and development, Q1 FY2026, three months to 2026-03-31$18.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure18.5Research and development, Q2 FY2026, three months to 2026-06-30$18.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Operating income$m(17.1)Operating income, Q3 FY2023, three months to 2023-09-30−$17.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure(25.5)Operating income, Q4 FY2023, three months to 2023-12-31−$25.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure(28.2)Operating income, Q1 FY2024, three months to 2024-03-31−$28.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure(26.6)Operating income, Q2 FY2024, three months to 2024-06-30−$26.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure(23.9)Operating income, Q3 FY2024, three months to 2024-09-30−$23.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(24.0)Operating income, Q4 FY2024, three months to 2024-12-31−$24.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure(22.9)Operating income, Q1 FY2025, three months to 2025-03-31−$22.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(21.1)Operating income, Q2 FY2025, three months to 2025-06-30−$21.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(18.5)Operating income, Q3 FY2025, three months to 2025-09-30−$18.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(23.9)Operating income, Q4 FY2025, three months to 2025-12-31−$23.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure(21.6)Operating income, Q1 FY2026, three months to 2026-03-31−$21.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(8.8)Operating income, Q2 FY2026, three months to 2026-06-30−$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.7Income tax, Q3 FY2023, three months to 2023-09-30$738.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure2.0Income tax, Q4 FY2023, three months to 2023-12-31$2.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-05-06, accession 0001628280-24-020455.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-08, accession 0001628280-24-035867.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(14.3)Net income, Q3 FY2023, three months to 2023-09-30−$14.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure(24.1)Net income, Q4 FY2023, three months to 2023-12-31−$24.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure(25.0)Net income, Q1 FY2024, three months to 2024-03-31−$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(23.0)Net income, Q2 FY2024, three months to 2024-06-30−$23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(19.1)Net income, Q3 FY2024, three months to 2024-09-30−$19.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(19.5)Net income, Q4 FY2024, three months to 2024-12-31−$19.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure(18.8)Net income, Q1 FY2025, three months to 2025-03-31−$18.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(17.9)Net income, Q2 FY2025, three months to 2025-06-30−$17.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(15.8)Net income, Q3 FY2025, three months to 2025-09-30−$15.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(21.7)Net income, Q4 FY2025, three months to 2025-12-31−$21.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure(19.9)Net income, Q1 FY2026, three months to 2026-03-31−$19.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(7.2)Net income, Q2 FY2026, three months to 2026-06-30−$7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Diluted EPS$ per share(0.34)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figurenot reported(0.59)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure(0.45)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure(0.31)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figurenot reported(0.30)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(0.28)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(0.25)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figurenot reported(0.29)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(0.10)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Basic EPS$ per share(0.34)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figurenot reported(0.59)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure(0.45)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure(0.31)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figurenot reported(0.30)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(0.28)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(0.25)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figurenot reported(0.29)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(0.10)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure

Balance sheet

Cash and equivalents$68.1m, Q2 FY2026
Shareholders' equity−$81.0m, Q2 FY2026
Foghorn Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m70.3Cash and equivalents, Q3 FY2023, at 2023-09-30$70.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure80.3Cash and equivalents, FY2023, at 2023-12-31$80.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-06, accession 0001628280-25-010933.Report this figure79.3Cash and equivalents, Q1 FY2024, at 2024-03-31$79.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure139Cash and equivalents, Q2 FY2024, at 2024-06-30$138.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure57.7Cash and equivalents, Q3 FY2024, at 2024-09-30$57.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure55.5Cash and equivalents, FY2024, at 2024-12-31$55.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-11, accession 0001628280-26-016814.Report this figure61.0Cash and equivalents, Q1 FY2025, at 2025-03-31$61.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure72.6Cash and equivalents, Q2 FY2025, at 2025-06-30$72.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure89.3Cash and equivalents, Q3 FY2025, at 2025-09-30$89.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure80.9Cash and equivalents, FY2025, at 2025-12-31$80.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure87.7Cash and equivalents, Q1 FY2026, at 2026-03-31$87.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure68.1Cash and equivalents, Q2 FY2026, at 2026-06-30$68.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Current assets$m265Current assets, Q3 FY2023, at 2023-09-30$265.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001628280-23-036187.Report this figure240Current assets, FY2023, at 2023-12-31$240.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-06, accession 0001628280-25-010933.Report this figure212Current assets, Q1 FY2024, at 2024-03-31$211.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-06, accession 0001628280-24-020455.Report this figure290Current assets, Q2 FY2024, at 2024-06-30$289.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-035867.Report this figure271Current assets, Q3 FY2024, at 2024-09-30$271.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure250Current assets, FY2024, at 2024-12-31$249.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-11, accession 0001628280-26-016814.Report this figure225Current assets, Q1 FY2025, at 2025-03-31$225.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure204Current assets, Q2 FY2025, at 2025-06-30$203.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure184Current assets, Q3 FY2025, at 2025-09-30$184.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure163Current assets, FY2025, at 2025-12-31$163.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure188Current assets, Q1 FY2026, at 2026-03-31$188.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure170Current assets, Q2 FY2026, at 2026-06-30$170.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Total assets$m313Total assets, Q3 FY2023, at 2023-09-30$313.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001628280-23-036187.Report this figure286Total assets, FY2023, at 2023-12-31$285.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-06, accession 0001628280-25-010933.Report this figure255Total assets, Q1 FY2024, at 2024-03-31$255.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-06, accession 0001628280-24-020455.Report this figure329Total assets, Q2 FY2024, at 2024-06-30$328.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001628280-24-035867.Report this figure308Total assets, Q3 FY2024, at 2024-09-30$308.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure284Total assets, FY2024, at 2024-12-31$284.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-11, accession 0001628280-26-016814.Report this figure259Total assets, Q1 FY2025, at 2025-03-31$258.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure226Total assets, Q2 FY2025, at 2025-06-30$226.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure205Total assets, Q3 FY2025, at 2025-09-30$205.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure198Total assets, FY2025, at 2025-12-31$198.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure222Total assets, Q1 FY2026, at 2026-03-31$222.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure203Total assets, Q2 FY2026, at 2026-06-30$203.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Current liabilities$m52.0Current liabilities, Q3 FY2023, at 2023-09-30$52.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001628280-23-036187.Report this figure58.4Current liabilities, FY2023, at 2023-12-31$58.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-06, accession 0001628280-25-010933.Report this figure52.1Current liabilities, Q1 FY2024, at 2024-03-31$52.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-06, accession 0001628280-24-020455.Report this figure50.9Current liabilities, Q2 FY2024, at 2024-06-30$50.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-035867.Report this figure56.8Current liabilities, Q3 FY2024, at 2024-09-30$56.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure67.0Current liabilities, FY2024, at 2024-12-31$67.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-11, accession 0001628280-26-016814.Report this figure71.3Current liabilities, Q1 FY2025, at 2025-03-31$71.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure77.8Current liabilities, Q2 FY2025, at 2025-06-30$77.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure85.1Current liabilities, Q3 FY2025, at 2025-09-30$85.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure59.7Current liabilities, FY2025, at 2025-12-31$59.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure64.4Current liabilities, Q1 FY2026, at 2026-03-31$64.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure50.6Current liabilities, Q2 FY2026, at 2026-06-30$50.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Total liabilities$m371Total liabilities, Q3 FY2023, at 2023-09-30$370.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001628280-23-036187.Report this figure363Total liabilities, FY2023, at 2023-12-31$363.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-06, accession 0001628280-25-010933.Report this figure352Total liabilities, Q1 FY2024, at 2024-03-31$352.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-06, accession 0001628280-24-020455.Report this figure343Total liabilities, Q2 FY2024, at 2024-06-30$342.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001628280-24-035867.Report this figure337Total liabilities, Q3 FY2024, at 2024-09-30$336.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure330Total liabilities, FY2024, at 2024-12-31$329.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-11, accession 0001628280-26-016814.Report this figure320Total liabilities, Q1 FY2025, at 2025-03-31$320.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure303Total liabilities, Q2 FY2025, at 2025-06-30$302.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure295Total liabilities, Q3 FY2025, at 2025-09-30$294.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure307Total liabilities, FY2025, at 2025-12-31$306.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure299Total liabilities, Q1 FY2026, at 2026-03-31$298.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure284Total liabilities, Q2 FY2026, at 2026-06-30$284.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m(57.4)Shareholders' equity, Q3 FY2023, at 2023-09-30−$57.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure(77.2)Shareholders' equity, FY2023, at 2023-12-31−$77.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-11, accession 0001628280-26-016814.Report this figure(97.5)Shareholders' equity, Q1 FY2024, at 2024-03-31−$97.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(14.3)Shareholders' equity, Q2 FY2024, at 2024-06-30−$14.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(28.3)Shareholders' equity, Q3 FY2024, at 2024-09-30−$28.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(45.5)Shareholders' equity, FY2024, at 2024-12-31−$45.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(61.7)Shareholders' equity, Q1 FY2025, at 2025-03-31−$61.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(76.7)Shareholders' equity, Q2 FY2025, at 2025-06-30−$76.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(89.7)Shareholders' equity, Q3 FY2025, at 2025-09-30−$89.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure(109)Shareholders' equity, FY2025, at 2025-12-31−$108.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(76.4)Shareholders' equity, Q1 FY2026, at 2026-03-31−$76.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure(81.0)Shareholders' equity, Q2 FY2026, at 2026-06-30−$81.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure

Cash flow

Operating cash flow−$17.8m, Q2 FY2026
Capital expenditure$50.0k, Q2 FY2026
Foghorn Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(27.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$27.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-04, accession 0001628280-24-045006. Derived: 9-month figure less the 6-month figure.Report this figure(27.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure(29.3)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$29.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure(25.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$25.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0001628280-25-037606. Derived: 6-month figure less the 3-month figure.Report this figure(21.0)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$21.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049238. Derived: 9-month figure less the 6-month figure.Report this figure(24.5)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$24.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure(24.0)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$24.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(21.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$21.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053819. Derived: 6-month figure less the 3-month figure.Report this figure(18.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$18.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001628280-25-049238. Derived: 9-month figure less the 6-month figure.Report this figure(22.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$22.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure(25.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$25.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure(17.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$17.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053819. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$82.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-04, accession 0001628280-24-045006. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-06, accession 0001628280-25-010933. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$101.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$17.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-05, accession 0001628280-25-037606. Derived: 6-month figure less the 3-month figure.Report this figure0.3Capital expenditure, Q3 FY2024, three months to 2024-09-30$309.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049238. Derived: 9-month figure less the 6-month figure.Report this figure0.5Capital expenditure, Q4 FY2024, three months to 2024-12-31$479.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$28.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$22.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053819. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001628280-25-049238. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-11, accession 0001628280-26-016814. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$50.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053819. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)70.63m, Q2 FY2026
Foghorn Therapeutics Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares41.7Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3041,672,621 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001628280-23-036187.Report this figure41.8Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3141,811,087 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-06, accession 0001628280-24-020455.Report this figure41.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3041,825,555 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001628280-24-035867.Report this figure42.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3042,025,938 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-04, accession 0001628280-24-045006.Report this figure42.4Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3142,428,813 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001628280-25-025312.Report this figure51.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3051,580,310 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0001628280-25-037606.Report this figure62.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3062,602,848 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure62.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3162,848,673 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure63.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3062,978,219 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure63.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3063,029,293 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001628280-25-049238.Report this figure69.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3169,540,075 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-031671.Report this figure70.6Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3070,629,419 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure

Shares outstanding: 59.39mShares outstanding, period not labelled, at 2026-07-3159,385,315 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001628280-26-053819.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.